Supplement
Omega-3 fatty acids
Omega-3 supplements have been tested in some of the largest prevention trials ever run. The results split cleanly by population: in generally healthy people, routine supplementation has not prevented cardiovascular disease or cancer; in specific high-risk patients, one high-dose purified preparation reduced cardiovascular events.
Quick verdict
No benefit for primary prevention in healthy adults in the largest trial. A high-dose purified EPA preparation reduced cardiovascular events in statin-treated patients with high triglycerides — a specific, prescription-level context often stretched to sell ordinary fish-oil capsules.
The assessment
Claim by claim
Each claim is graded on its own evidence. A grade for one claim says nothing about the others.
| Claim | What was measured | Evidence |
|---|---|---|
| Reduces cardiovascular events in statin-treated patients with high triglycerides | Disease outcome | Early |
| Prevents cardiovascular disease and cancer in generally healthy adults | Disease outcome | Against |
Reduces cardiovascular events in statin-treated patients with high triglycerides
Early human evidenceOutcome measured: Disease outcome — A diagnosed condition or clinical event was measured.
REDUCE-IT randomised 8,179 statin-treated patients with elevated triglycerides to 4 g/day icosapent ethyl (purified EPA) or placebo. Cardiovascular events fell significantly over a median 4.9 years.
Why this grade — the appraisal in full
One or a small number of small, short or preliminary human studies. Directionally interesting, not yet dependable.
- Strongest study design. Randomised controlled trial with 8,179 participants.
- Human research volume. 1 human study, 8,179 participants in total.
- What was measured. 1 human study measured a clinical or functional outcome rather than a laboratory marker alone.
- Replication. The supporting result has not been independently replicated in humans.
- Study duration. Longest human study ran 255 weeks.
- Funding and conflicts. 1 of 1 human studies were funded by, or authored by, a party with a commercial interest in the result.
Limitations. A prescription-dose purified EPA product in a defined high-risk population, funded by its manufacturer; the mineral-oil placebo has been debated. It is not evidence for over-the-counter fish oil in healthy people.
| Study | Design | Population | Finding |
|---|---|---|---|
| [1]Cardiovascular Risk Reduction with Icosapent Ethyl for HypertriglyceridemiaThe New England journal of medicine · 2019 · PMID 30415628 | Randomised controlled trialHuman | 8,179 participantsParticipants with a diagnosed condition | Supports the claimREDUCE-IT: manufacturer-funded; 25% relative reduction in the primary composite cardiovascular endpoint. |
Prevents cardiovascular disease and cancer in generally healthy adults
Evidence against the claimOutcome measured: Disease outcome — A diagnosed condition or clinical event was measured.
The VITAL trial randomised 25,871 healthy US adults to 1 g/day marine omega-3 or placebo for a median 5.3 years. Neither major cardiovascular events nor invasive cancer was reduced.
Why this grade — the appraisal in full
Well-conducted human research indicates the claimed effect does not occur, or is too small to matter.
- Strongest study design. Randomised controlled trial with 25,871 participants.
- Human research volume. 1 human study, 25,871 participants in total.
- What was measured. 1 human study measured a clinical or functional outcome rather than a laboratory marker alone.
- Replication. The supporting result has not been independently replicated in humans.
- Study duration. Longest human study ran 276 weeks.
Limitations. Applies to routine supplementation in unselected healthy adults at 1 g/day; higher doses and higher-risk groups are separate questions, addressed by other trials.
| Study | Design | Population | Finding |
|---|---|---|---|
| [2]Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and CancerThe New England journal of medicine · 2019 · PMID 30415637 | Randomised controlled trialHuman | 25,871 participantsHealthy participants | Found no effectVITAL: 1 g/day omega-3 vs placebo; null for major cardiovascular events and invasive cancer. |
Human evidence
2 studies in people.
- [1]Randomised controlled trial · 8,179 participants
- [2]Randomised controlled trial · 25,871 participants
Animal and laboratory evidence
Shown separately, and never used to support a human claim.
No preclinical study is currently linked on this page.
Before anything else
Safety and interactions
Generally well tolerated; the high-dose EPA trial recorded a small increase in atrial fibrillation and bleeding. Interacts with anticoagulants — check before combining.
Practical guidance
If you decide to buy
If you eat oily fish twice a week, the trials give you no reason to buy capsules. The honest purchase case is dietary: you do not eat fish, and you want the intake the dietary guidance is based on — not the cardiovascular protection VITAL failed to find.
- Which form
- Standard fish-oil or algae-oil (vegetarian) capsules delivering EPA and DHA. The prescription product that reduced events in REDUCE-IT is purified EPA at 4 g/day — ordinary capsules are not that product and should not be bought on its results.
- Typical evidence-aligned dose
- About 450 mg combined EPA and DHA per day approximates the oily-fish guidance. Check the EPA+DHA line on the label, not the 'fish oil' headline number — they differ several-fold.
- Quality and testing
- Oxidation is the real quality issue with fish oil. Prefer products with a recent batch date and a third-party mark (IFOS, Informed Sport); a rancid smell on cutting a capsule open is a fair reason to bin the bottle.
- Buying in the UK
- Supermarket and pharmacy own-brands routinely pass quality testing in the UK; price tracks marketing more than quality. On statins with high triglycerides? The relevant preparation is prescription-only — talk to your GP, do not self-substitute retail capsules.
Disclosure: Longevity Record is commercially connected to Vitality Supplements. This guidance names no brands, links to no shop, and is written from the trial literature — the grades above were computed before this section was, and no commercial consideration can change them.
The ledger
Grade history
No grade on this page has changed since tracking began. When one moves — a new trial, a retraction, a corrected appraisal — the change is detected automatically and recorded on the public ledger.
Falsifiability
What would change our view
Replication of cardiovascular benefit in broader populations, or any randomised evidence for mortality benefit in healthy adults.
Check everything
Sources
Every citation links to its PubMed record. Bibliographic details are retrieved from PubMed, not written by us.
- [1]Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia Bhatt DL et al.. The New England journal of medicine. 2019. PMID 30415628 · doi:10.1056/NEJMoa1812792
- [2]Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer Manson JE et al.. The New England journal of medicine. 2019. PMID 30415637 · doi:10.1056/NEJMoa1811403